Adoptive T-Cell Therapy Congress

Join them at the Adoptive T-Cell Therapy Congress, taking place March 15-16, 2016 to learn from, meet and network with 100+ scientists from academia, research and industry all working to develop state of the art T-cell therapies focusing on safety, efficacy and commercialisation.

Join the industry’s scientific and business leaders as they discuss adoptive T-cell therapies for cancer by looking at ways forward in improving efficiency and efficacy, case studies on liquid and solid tumours, scalability, manufacture and progress within industry regulation. The congress will focus on academic collaboration, networking and business partnering within the fields of CAR-T, TCR's and TIL's with sessions including: advancements in T-cell engineering; efficacy in different cancer models and results from human and clinical studies.

Attending the congress brings you together with thought leaders from biotech, big pharma and academia and the wider service community and gives you access to strategies that are critical to furthering the development of viable T-cell therapies.

Hosted by Kisaco Research, this B2B Adoptive T-Cell Therapy Congress conference will cover:
• Advancements in T-cell engineering
• Efficacy in different cancer models
• Results from human and clinical studies
• Commercialisation of Viable T-cell therapies
• Scaling and manufacture of T-cell